Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rosemary Ecob"'
Autor:
Rachael E. Faulkner, Samuel N. Outteridge, David H. Dockrell, Robert F. Storey, Rosemary Ecob, Laura West, Mark R Thomas, Fladia Phoenix, Ramzi Ajjan, Heather M Judge, Haroon Khan, Ian Sabroe, Gurpreet K. Sangha
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 35:2562-2570
Objective— Clinical studies suggest that platelet P2Y 12 inhibitors reduce mortality from sepsis, although the underlying mechanisms have not been clearly defined in vivo. We hypothesized that P2Y 12 inhibitors may improve survival from sepsis by s
Autor:
Clare Wales, Heather M Judge, Jemma Victoria Walker, Robert F. Storey, Rajiv R. Joshi, Allison Morton, Arun Karunakaran, Rosemary Ecob, Rashed Hossain
Publikováno v:
Platelets. 25:416-422
Dual antiplatelet therapy consisting of clopidogrel in addition to aspirin has previously been the standard of care for patients with acute coronary syndromes (ACS) but international guidelines have been evolving over the last 4 years with the introd
Autor:
Robert F. Storey, Kate E Howgego, Wael Sumaya, Rosemary Ecob, Rebecca L Daly, Amrita J Dhutia, Sonal Mehra, Heather M Judge, Allison Morton
Publikováno v:
Thrombosis and Haemostasis. 109:550-555
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant
Autor:
Allison Morton, Heather M Judge, Rajiv R. Joshi, Wael Sumaya, Rosemary Ecob, Robert F. Storey
Publikováno v:
Platelets. 26:271-273
Antiplatelet therapy plays a central role in the management of ischaemic heart disease [1]. While poor inhibition of P2Y12 receptor has been linked to higher incidence of ischaemic events, enhanced...
Autor:
Richard C. Becker, Dominick J. Angiolillo, Bhaloo Desai, Robert F. Storey, Rosemary Ecob, Lars Wallentin, Shankar B. Patil, Håkan Emanuelsson, Steen Husted, Christopher P. Cannon
Publikováno v:
Journal of the American College of Cardiology. 56:1456-1462
Objectives The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes. ...
Autor:
Wael, Sumaya, Rebecca L, Daly, Sonal, Mehra, Amrita J, Dhutia, Kate E, Howgego, Rosemary, Ecob, Heather M, Judge, Allison C, Morton, Robert F, Storey
Publikováno v:
Thrombosis and haemostasis. 109(3)
VerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for pl
Autor:
Cheryl Wei, Robert F. Storey, Rosemary Ecob, Kathleen Butler, Paul A. Gurbel, Kevin P. Bliden, Arun Karunakaran, U. S. Tantry
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 9(9)
The rate of recovery of platelet function after discontinuation of P2Y(12) inhibitors depends on the reversibility of the antiplatelet effect and the extent of the on-treatment response. P2Y(12) inhibition increases the bleeding risk in patients requ
Autor:
Robert F, Storey, Dominick J, Angiolillo, Shankar B, Patil, Bhaloo, Desai, Rosemary, Ecob, Steen, Husted, Hakan, Emanuelsson, Christopher P, Cannon, Richard C, Becker, Lars, Wallentin
Publikováno v:
Journal of the American College of Cardiology. 56(18)
The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes.The PLATO study demonstrated superiority of ticagrelor over clopi
Autor:
Robert F, Storey, Kevin P, Bliden, Shankar B, Patil, Arun, Karunakaran, Rosemary, Ecob, Kathleen, Butler, Renli, Teng, Cheryl, Wei, Udaya S, Tantry, Paul A, Gurbel
Publikováno v:
Journal of the American College of Cardiology. 56(3)
ObjectivesWe prospectively assessed cardiac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET (A Multi-Centre Randomised, Double-Blind, Double-Dummy Paral